Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL17802152

C[S+]([O-])CCC#N.O=C(O)C(F)(F)F

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
MLYCD O95822 2/20 0.31
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22272369 0.79
SCHEMBL124304 0.79
Acetonitrile SCHEMBL19611744 0.75 ALDH1A1 (0.35)
Trifluoroacetic Acid SCHEMBL27762565 0.74 TSHR (0.39) MLYCDMEN1KMT2A
Trifluoroacetic Acid SCHEMBL4182370 0.72 ALDH1A1 (0.35)
Trifluoroacetic Acid SCHEMBL4069871 0.72 ALDH1A1 (0.35)
Trifluoroacetic Acid SCHEMBL1024065 0.71 MEN1 (0.35) MLYCDMEN1KMT2A
Trifluoroacetic Acid SCHEMBL30054036 0.71 TSHR (0.58) MLYCDMEN1KMT2A
Trifluoroacetic Acid SCHEMBL23043751 0.71 ALDH1A1 (0.47) MLYCDMEN1KMT2A
Trifluoroacetic Acid SCHEMBL27350364 0.71 ALDH1A1 (0.47) MLYCDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10933025-B2 Nanoparticles for encapsulating compounds, the preparation and uses thereof INNOUP FARMA, S.L. (ES) 2021-03-02 US disclosed
US-20170326074-A1 NANOPARTICLES FOR ENCAPSULATING COMPOUNDS, THE PREPARATION AND USES THEREOF INNOUP FARMA, S.L. (ES) 2017-11-16 US disclosed
EP-3233126-A1 NANOPARTICLES FOR ENCAPSULATING COMPOUNDS, THE PREPARATION AND USES THEREOF Innoup Farma, S.L. (ES) 2017-10-25 EP disclosed
WO-2016087340-A1 NANOPARTICLES FOR ENCAPSULATING COMPOUNDS, THE PREPARATION AND USES THEREOF INNOUP FARMA, S.L. (ES) 2016-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170326074-A1 NANOPARTICLES FOR ENCAPSULATING COMPOUNDS, THE PREPARATION AND USES THEREOF NCL, CD47, DSTN MLYCD 3316/4885MEN1 1753/4885KMT2A 3388/4885
US-10933025-B2 Nanoparticles for encapsulating compounds, the preparation and uses thereof NCL, CD47, DSTN MLYCD 3316/4885MEN1 1753/4885KMT2A 3388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.